Catenae Innovation PLC (LON:CTEA) has said it is forming a joint-venture with the UK and South African arms of BHA-Medical to deliver an integrated coronavirus (COVID-19) test, monitor and manage programme that can be used by governments, businesses and other organisations.
The AIM-listed technology and media group is the developer of the Cov-ID electronic passport, while BHA has supplied 350,000 three-antibody tests in the UK to customers including two FTSE 100 companies.
BHA will provide both the three-antibody and Healgen antigen tests to the JV. Both deliver results in 20 minutes.
Catenae's technology will be used to store results, allowing administrators accessing its Data Intelligence Dashboard to monitor the health of people while responding to coronavirus outbreaks and hotspots.
In a statement, Catenae chief executive Guy Meyer said: "BHA-Medical and ourselves are strategically aligned given that we complement each other's offering.
“Our revenue models are both volume-based and both have the capacity to scale. BHA-Medical's presence in South Africa also dovetails into the current market activity that Afrik-ID are undertaking across the SADC region from neighbouring Botswana.”